A prospective Phase Ib trial that enrolled 14 patients with advanced and/or metastatic melanoma (stage IIIc/IV) combined ICI with TNF blockade (infliximab or certolizumab) and demonstrated favorable tumor outcomes: seven of seven evaluable patients achieved objective response with 4 CRs and 3 PRs (74). Here, TNF is linked to metastatic melanoma.